Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook


 


 

Illumina wins NIPT patent case in UK High Court

27 November 2017

By Dr Rachel Brown

Appeared in BioNews 928

The UK Patents Court has ruled that two separate non-invasive prenatal tests (NIPT) infringe patents licensed by the US firm Illumina.

Illumina successfully claimed that the Iona test offered by Premaitha Health was in infringement of five patents, and a gender testing component of Ariosa Diagnostics' Harmony test infringed one patent. Unless the judgment is successfully appealed, both tests may be subject to restrictions limiting their sale on the UK market.

Charles Dadswell, Senior Vice President and General Counsel at Illumina has said: 'We are pleased that the court ruled in our favour. The court's judgment validates the investments Illumina has made, the value of this technology and the significant contributions of the inventors in this field.'

Tests such as Iona and Harmony can detect either the gender of the fetus or chromosomal anomalies by assaying fetal cfDNA in the mother's blood. The techniques are therefore considered to be 'non-invasive' forms of prenatal testing, and offer women an alternative to methods such as amniocentesis and CVS that involve sampling cells from the amniotic fluid and placenta respectively, and are associated with increased risk of miscarriage.

NIPT is available on the NHS for pregnancies considered to be at high risk of trisomies (See BioNews 876). Premaitha's contracts to provide Iona to over 50 NHS hospitals could potentially be affected by the ruling.

The court heard claims involving three different patent families licensed by Illumina: Lo 1, Lo 2&3, and Quake 1&2, named for the scientists on whose work they are based (Professor Dennis Lo of the Chinese University of Hong Kong, and Dr Stephen Quake from Stanford University in California respectively). The patents are owned by the universities, except Lo1 which is held by US firm Sequenom, who offer their own NIPT product: MaterniT21. Illumina claimed that it held exclusive licences for all five.

Both Premaitha and Ariosa claimed that the patents under which they are sued are invalid. However, the court ruled in favour of Illumina, stating that all patents are valid and that the tests involved do, at least in some circumstances, infringe upon them. It is expected that the decision will be appealed by the defendants.

Dr Stephen Little, CEO of Premaitha Health, said: 'We are very disappointed with this ruling and deeply disagree with the interpretation the Judge has given to precise technical language in the patents. The effect of the judgment could potentially limit the access of UK patients to NIPT and, in certain respects, diverges from decisions made in other jurisdictions. We are seeking leave to appeal and continue to believe that the motivation behind these legal actions is competitive rather than technical.'

SOURCES & REFERENCES
GenomeWeb | 21 November 2017
 
Business Wire | 21 November 2017
 
British and Irish Legal Information Institute | 21 November 2017
 
Life Sciences Intellectual Property Review | 22 November 2017
 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

29 February 2016 - by Ryan Ross 
The California-based genome-sequencing company Illumina has accused UK rival Oxford Nanopore Technologies of violating its intellectual property rights...
07 December 2015 - by Antony Blackburn-Starza 
The US federal court of appeals has declined to rehear arguments on the patentability of a prenatal blood test, saying that it remains bound by the Supreme Court to determine the claims as non-patentable...
22 June 2015 - by Ceri Durham 
A US federal appeals court has upheld a ruling that Sequenom's prenatal MaterniT21 test is not sufficiently 'inventive' to be patentable....
20 October 2014 - by Sean Byrne 
Illumina has announced the first three companies in its Accelerator Programme, designed to help genomics start-ups as other sources of funding grow scarce...
26 August 2014 - by Dr Molly Godfrey 
The DNA sequencing company Illumina have announced collaborations with three major pharmaceutical companies - AstraZeneca, Sanofi and Johnson & Johnson - to develop a single test for several gene mutations in cancer...

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Andy Greenfield

Dr Anna Smajdor

Dr Henry Malter

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross

Sandy Starr


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation